

ARG51741 anti-RelB phospho (Ser573) antibody

Package: 100 µl, 50 µl
Store at: -20°C

Summary

Product Description	Rabbit Polyclonal antibody recognizes RelB phospho (Ser573)
Tested Reactivity	Hu, Ms
Tested Application	IHC-P, WB
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Target Name	RelB
Species	Human
Immunogen	Peptide sequence around phosphorylation site of serine 573 (L-L-S(p)-P-G) derived from Human RelB.
Conjugation	Un-conjugated
Alternate Names	REL-B; IREL; I-Rel; I-REL; Transcription factor RelB


Application Instructions

Application table	Application	Dilution
	IHC-P	1:50 - 1:100
	WB	1:500 - 1:1000
Application Note	* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.	

Properties


Form	Liquid
Purification	Antibodies were produced by immunizing rabbits with KLH-conjugated synthetic phosphopeptide. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. In addition, non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Buffer	PBS (without Mg ²⁺ and Ca ²⁺ , pH 7.4), 150mM NaCl, 0.02% Sodium azide and 50% Glycerol.
Preservative	0.02% Sodium azide
Stabilizer	50% Glycerol
Concentration	1 mg/ml
Storage instruction	For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note	For laboratory research only, not for drug, diagnostic or other use.

Database links	GeneID: 19698 Mouse GeneID: 5971 Human Swiss-port # Q01201 Human Swiss-port # Q04863 Mouse
Gene Symbol	RELB
Gene Full Name	v-rel avian reticuloendotheliosis viral oncogene homolog B
Background	NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.
Function	NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. [UniProt]
Highlight	Related products: Anti-Rabbit IgG secondary antibodies; Related poster download: The NF-kappa B Pathways.pdf
Research Area	Cancer antibody; Cell Biology and Cellular Response antibody; Cell Death antibody; Gene Regulation antibody; Signaling Transduction antibody
Calculated Mw	62 kDa
PTM	Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.



ARG51741 anti-RelB phospho (Ser573) antibody WB image

Western blot: Extracts from HUVEC cells untreated or treated with TNF stained with ARG51741 anti-RelB phospho (Ser573) antibody.



ARG51741 anti-RelB phospho (Ser573) antibody IHC-P image

Immunohistochemistry: Paraffin-embedded Human breast carcinoma tissue stained with ARG51741 anti-RelB phospho (Ser573) antibody (left) or the same antibody preincubated with blocking peptide (right).